Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies
Status:
Completed
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
This study will determine the long-term safety, tolerability, and efficacy of tirabrutinib in
adults in a prior tirabrutinib study and whose disease had not progressed on the parent
study. The dosing regimen will be based on the prior dosing regimen from the parent study.